R1 RCM Inc. (NASDAQ:RCM) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of R1 RCM Inc. (NASDAQ:RCM – Get Rating) have been given a consensus rating of “Moderate Buy” by the seventeen brokerages that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $17.44.

A number of analysts have commented on the stock. Robert W. Baird began coverage on shares of R1 RCM in a report on Tuesday, April 11th. They set an “outperform” rating and a $18.00 target price for the company. Canaccord Genuity Group lifted their target price on R1 RCM from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, February 17th. Royal Bank of Canada upped their price target on R1 RCM from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Thursday, February 2nd. Truist Financial downgraded R1 RCM from a “buy” rating to a “hold” rating and set a $15.00 price objective on the stock. in a research note on Thursday, February 2nd. Finally, Stephens began coverage on shares of R1 RCM in a report on Tuesday, April 11th. They issued an “overweight” rating and a $18.00 target price for the company.

Insider Activity at R1 RCM

In other news, President John M. Sparby sold 20,000 shares of the company’s stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $16.36, for a total value of $327,200.00. Following the transaction, the president now directly owns 243,827 shares in the company, valued at $3,989,009.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, President John M. Sparby sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $16.36, for a total value of $327,200.00. Following the transaction, the president now owns 243,827 shares of the company’s stock, valued at $3,989,009.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Lee Rivas acquired 71,767 shares of R1 RCM stock in a transaction on Tuesday, February 21st. The shares were purchased at an average price of $13.93 per share, for a total transaction of $999,714.31. Following the completion of the acquisition, the chief executive officer now directly owns 71,767 shares in the company, valued at $999,714.31. The disclosure for this purchase can be found here. 37.00% of the stock is owned by company insiders.

Institutional Trading of R1 RCM

A number of hedge funds have recently bought and sold shares of RCM. Point72 Middle East FZE bought a new stake in shares of R1 RCM in the 4th quarter valued at about $29,000. Captrust Financial Advisors boosted its stake in R1 RCM by 81.7% in the second quarter. Captrust Financial Advisors now owns 1,664 shares of the healthcare provider’s stock valued at $35,000 after acquiring an additional 748 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in R1 RCM by 67.2% in the first quarter. Parkside Financial Bank & Trust now owns 2,972 shares of the healthcare provider’s stock valued at $45,000 after acquiring an additional 1,195 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in R1 RCM by 2,483.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,624 shares of the healthcare provider’s stock worth $85,000 after purchasing an additional 4,445 shares during the last quarter. Finally, Macquarie Group Ltd. increased its position in shares of R1 RCM by 11.0% during the second quarter. Macquarie Group Ltd. now owns 4,159 shares of the healthcare provider’s stock worth $88,000 after purchasing an additional 411 shares in the last quarter. Hedge funds and other institutional investors own 97.09% of the company’s stock.

R1 RCM Price Performance

R1 RCM stock opened at $16.86 on Friday. R1 RCM has a one year low of $6.71 and a one year high of $27.07. The business’s fifty day moving average is $15.14 and its 200 day moving average is $13.01. The stock has a market capitalization of $7.05 billion, a PE ratio of -73.30, a price-to-earnings-growth ratio of 12.18 and a beta of 0.84.

R1 RCM (NASDAQ:RCM – Get Rating) last issued its earnings results on Thursday, February 16th. The healthcare provider reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.06). The company had revenue of $532.80 million during the quarter, compared to analysts’ expectations of $519.28 million. R1 RCM had a negative return on equity of 1.02% and a negative net margin of 4.41%. The company’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.11 EPS. As a group, sell-side analysts expect that R1 RCM will post 0.08 EPS for the current fiscal year.

About R1 RCM

(Get Rating)

R1 RCM, Inc engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.